ClinicalTrials.gg
CompletedNCT04657016SURMOUNT-3Updated May 16, 2024Results posted

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 65 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
579
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
13th of 104
579 · median 69
Started
2021
with 5 others
Phase 3
26 of 104
7 open now
Registered
5th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 13th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Diet
  • Exercise
  • Metabolism and Nutrition Disorder
  • Behavioral Modification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) ≥30 kg/m2 or ≥27 kg/m2 and previously diagnosed with at least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
  • History of at least one unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Change in body weight greater than 5 kg within 3 months prior to starting study
  • Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
  • History of pancreatitis
  • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
579 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants received weekly doses of tirzepatide subcutaneously (SC) for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received matching placebo SC once weekly (QW).

    Other: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • OtherPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  2. Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction

    Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression model using imputed data with baseline body weight, Analysis Country, Sex, Treatment as factors.

    Time frame: Week 72

Secondary outcomes

  1. Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program

    Percentage of participants who maintain ≥80% of the body weight lost during intensive lifestyle program was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

    Time frame: 72 Weeks

  2. Percentage of Participants Who Achieve ≥10%Body Weight Reduction

    Percentage of participants who achieve ≥10% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

    Time frame: 72 Weeks

  3. Percentage of Participants Who Achieve ≥15% Body Weight Reduction

    Percentage of participants who achieve ≥15% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

    Time frame: 72 Weeks

  4. Percentage of Participants Who Achieve ≥20% Body Weight Reduction

    Percentage of participants who achieve ≥20% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

    Time frame: 72 Weeks

  5. Change From Baseline in Waist Circumference

    Change from baseline in waist circumference. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  6. Change From Baseline in Body Weight

    Change from baseline in body weight. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  7. Change From Baseline in Body Mass Index (BMI)

    Change from baseline in BMI. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  8. Change From Baseline in Systolic Blood Pressure (SBP)

    Change from baseline in SBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  9. Change From Baseline in Diastolic Blood Pressure (DBP)

    Change from baseline in DBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  10. Percent Change From Baseline in Total Cholesterol

    Percent change from baseline in total cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  11. Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol

    Percent change from baseline in HDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  12. Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol

    Percent change from baseline in LDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  13. Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol

    Percent change from baseline in VLDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  14. Percent Change From Baseline in Triglycerides

    Percent change from baseline in triglycerides. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  15. Percent Change From Baseline in Free Fatty Acids

    Percent change from baseline in free fatty acids. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  16. Change From Baseline in Fasting Glucose

    Change from baseline in fasting glucose. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  17. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  18. Percent Change From Baseline in Fasting Insulin

    Percent change from baseline in fasting insulin. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, 72 Weeks

  19. Change From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score

    The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, 72 Weeks

  20. Change From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined using ANCOVA model with Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, 72 Weeks

07

Results

Posted May 16, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboTirzepatide
Started292287
Received at least one dose of study drug292287
Completed227252
Not completed6535
Withdrew: Adverse event24
Withdrew: Death11
Withdrew: Lost to follow-up2412
Withdrew: Physician decision12
Withdrew: Pregnancy22
Withdrew: Protocol deviation10
Withdrew: Withdrawal by subject2814
Withdrew: Other - as reported by the investigator60

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight
Percent changePlaceboTirzepatide
Percent Change From Baseline in Body Weight3.3 ± 0.60-21.1 ± 0.59
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -24.5 · 95% CI -26.1 to -22.8
PrimaryPercentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction

Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression model using imputed data with baseline body weight, Analysis Country, Sex, Treatment as factors.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
percentage of participantsPlaceboTirzepatide
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction10.6594.37
Statistical analysis
  • Placebo vs Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 130.36 · 95% CI 69.98 to 242.84
SecondaryPercentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program

Percentage of participants who maintain ≥80% of the body weight lost during intensive lifestyle program was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

Time frame:
72 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program
percentage of participantsPlaceboTirzepatide
Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program37.8098.59
Statistical analysis
  • Placebo vs Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 101.60 · 95% CI 39.17 to 263.55
SecondaryPercentage of Participants Who Achieve ≥10%Body Weight Reduction

Percentage of participants who achieve ≥10% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

Time frame:
72 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≥10%Body Weight Reduction
percentage of participantsPlaceboTirzepatide
Percentage of Participants Who Achieve ≥10%Body Weight Reduction4.8188.03
Statistical analysis
  • Placebo vs Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 153.95 · 95% CI 78.90 to 300.37
SecondaryPercentage of Participants Who Achieve ≥15% Body Weight Reduction

Percentage of participants who achieve ≥15% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

Time frame:
72 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of participantsPlaceboTirzepatide
Percentage of Participants Who Achieve ≥15% Body Weight Reduction2.0673.94
Statistical analysis
  • Placebo vs Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 144.48 · 95% CI 62.65 to 333.21
SecondaryPercentage of Participants Who Achieve ≥20% Body Weight Reduction

Percentage of participants who achieve ≥20% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.

Time frame:
72 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥20% Body Weight Reduction
Percentage of participantsPlaceboTirzepatide
Percentage of Participants Who Achieve ≥20% Body Weight Reduction1.0354.93
Statistical analysis
  • Placebo vs Tirzepatide · Regression, Logistic · p = <0.001 · Odds ratio (or): 118.06 · 95% CI 40.08 to 347.74
SecondaryChange From Baseline in Waist Circumference

Change from baseline in waist circumference. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Centimeters (Cms)
Change From Baseline in Waist Circumference
Centimeters (Cms)PlaceboTirzepatide
Change From Baseline in Waist Circumference1.1 ± 0.58-16.8 ± 0.56
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -17.9 · 95% CI -19.5 to -16.3
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgPlaceboTirzepatide
Change From Baseline in Body Weight3.5 ± 0.67-21.5 ± 0.65
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -25.0 · 95% CI -26.9 to -23.2
SecondaryChange From Baseline in Body Mass Index (BMI)

Change from baseline in BMI. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · kilogram per meter square (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
kilogram per meter square (kg/m^2)PlaceboTirzepatide
Change From Baseline in Body Mass Index (BMI)1.2 ± 0.23-7.7 ± 0.23
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -8.9 · 95% CI -9.6 to -8.3
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

Change from baseline in SBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)PlaceboTirzepatide
Change From Baseline in Systolic Blood Pressure (SBP)4.4 ± 0.76-5.8 ± 0.73
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -10.2 · 95% CI -12.2 to -8.1
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP)

Change from baseline in DBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure (DBP)
mmHgPlaceboTirzepatide
Change From Baseline in Diastolic Blood Pressure (DBP)2.3 ± 0.53-3.4 ± 0.51
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -5.7 · 95% CI -7.2 to -4.3
SecondaryPercent Change From Baseline in Total Cholesterol

Percent change from baseline in total cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Total Cholesterol
Percent changePlaceboTirzepatide
Percent Change From Baseline in Total Cholesterol5.19 ± 1.11-3.00 ± 0.97
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -7.79 · 95% CI -10.40 to -5.10
SecondaryPercent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol

Percent change from baseline in HDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol
Percent changePlaceboTirzepatide
Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol3.6 ± 1.1215.4 ± 1.19
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): 11.4 · 95% CI 8.2 to 14.7
SecondaryPercent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol

Percent change from baseline in LDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol
Percent changePlaceboTirzepatide
Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol6.14 ± 1.71-6.07 ± 1.44
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -11.50 · 95% CI -15.30 to -7.53
SecondaryPercent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol

Percent change from baseline in VLDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol
Percent changePlaceboTirzepatide
Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol3.0 ± 2.32-25.6 ± 1.60
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -27.8 · 95% CI -32.1 to -23.2
SecondaryPercent Change From Baseline in Triglycerides

Percent change from baseline in triglycerides. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Triglycerides
Percent changePlaceboTirzepatide
Percent Change From Baseline in Triglycerides3.0 ± 2.34-25.8 ± 1.61
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -28.0 · 95% CI -32.3 to -23.4
SecondaryPercent Change From Baseline in Free Fatty Acids

Percent change from baseline in free fatty acids. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Free Fatty Acids
Percent changePlaceboTirzepatide
Percent Change From Baseline in Free Fatty Acids-15.0 ± 2.95-33.1 ± 2.20
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -21.3 · 95% CI -28.4 to -13.6
SecondaryChange From Baseline in Fasting Glucose

Change from baseline in fasting glucose. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Milligram per deciliter (mg/dL)
Change From Baseline in Fasting Glucose
Milligram per deciliter (mg/dL)PlaceboTirzepatide
Change From Baseline in Fasting Glucose2.4 ± 0.86-8.8 ± 0.82
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -11.2 · 95% CI -13.5 to -8.8
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1cPlaceboTirzepatide
Change From Baseline in Hemoglobin A1c (HbA1c)0.01 ± 0.022-0.46 ± 0.020
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.47 · 95% CI -0.53 to -0.42
SecondaryPercent Change From Baseline in Fasting Insulin

Percent change from baseline in fasting insulin. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Fasting Insulin
Percent changePlaceboTirzepatide
Percent Change From Baseline in Fasting Insulin17.3 ± 4.95-39.1 ± 2.46
Statistical analysis
  • Placebo vs Tirzepatide · Mixed Models Analysis · p = <0.001 · Mean difference (net): -48.1 · 95% CI -53.7 to -41.7
SecondaryChange From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score

The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · T-score
Change From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score
T-scorePlaceboTirzepatide
Change From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score-0.6 ± 0.393.3 ± 0.37
Statistical analysis
  • Placebo vs Tirzepatide · ANCOVA · p = <0.001 · Mean difference (net): 3.8 · 95% CI 2.8 to 4.9
SecondaryChange From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined using ANCOVA model with Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, 72 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
score on a scalePlaceboTirzepatide
Change From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score1.1 ± 1.1713.9 ± 1.10
Statistical analysis
  • Placebo vs Tirzepatide · ANCOVA · p = <0.001 · Mean difference (net): 12.8 · 95% CI 9.7 to 16.0

Adverse events

Collected over Baseline up to week 76. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/292 (0.3%)14/292 (4.8%)172/292 (58.9%)
Tirzepatide1/287 (0.3%)17/287 (5.9%)230/287 (80.1%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPlaceboTirzepatide
NephrolithiasisRenal and urinary disorders3/2920/287
Acute myocardial infarctionCardiac disorders0/2921/287
Colitis microscopicGastrointestinal disorders0/2921/287
HaematocheziaGastrointestinal disorders0/2921/287
PancreatitisGastrointestinal disorders0/2921/287
Small intestinal obstructionGastrointestinal disorders1/2921/287
Umbilical herniaGastrointestinal disorders0/2921/287
Cholecystitis acuteHepatobiliary disorders0/2921/287
CellulitisInfections and infestations1/2921/287
SepsisInfections and infestations1/2921/287
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboTirzepatide
NauseaGastrointestinal disorders41/292114/287
DiarrhoeaGastrointestinal disorders27/29289/287
Covid-19Infections and infestations74/29266/287
ConstipationGastrointestinal disorders20/29266/287
VomitingGastrointestinal disorders4/29252/287
Injection site reactionGeneral disorders3/29232/287
Abdominal painGastrointestinal disorders7/29230/287
DyspepsiaGastrointestinal disorders9/29227/287
Decreased appetiteMetabolism and nutrition disorders12/29227/287
HeadacheNervous system disorders22/29227/287

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboTirzepatideTotal
Mean45.70 ± 11.7945.40 ± 12.5945.60 ± 12.18
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTirzepatideTotal
Female183181364
Male109106215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTirzepatideTotal
Hispanic or Latino161151312
Not Hispanic or Latino129132261
Unknown or Not Reported246
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTirzepatideTotal
American Indian or Alaska Native426
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American323163
White252246498
More than one race268
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboTirzepatideTotal
Argentina444387
Brazil6059119
United States188185373
Body weight
Body weight(Kilograms (kg))PlaceboTirzepatideTotal
Mean101.29 ± 20.67102.47 ± 22.11101.87 ± 21.39
08

Study locations

65 sites
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • National Research Institute - Wilshire
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • National Research Institute (NRI) - Santa Ana
    Santa Ana, California 92704, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Clinical Research of West Florida
    Tampa, Florida 33606, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Elite Clinical Trials
    Rexburg, Idaho 83440, United States
  • Evanston Premier Healthcare Research LLC
    Evanston, Illinois 60201, United States
  • American Health Network of IN, LLC
    Avon, Indiana 46123, United States
  • American Health Network of IN, LLC
    Franklin, Indiana 46131, United States
  • American Health Network of IN, LLC
    Muncie, Indiana 47304, United States
  • Cotton O'Neil Mulvane
    Topeka, Kansas 66606, United States
  • Tandem Clinical Research,LLC
    Marrero, Louisiana 70072, United States
  • The National Diabetes & Obesity Research Institute
    Biloxi, Mississippi 39532, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada 89148, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Wake Forest University Baptist Medical Center (WFUBMC)
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44122, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Detweiler Family Medicine & Associates
    Lansdale, Pennsylvania 19446, United States
  • Penn Medicine: University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
    Pittsburgh, Pennsylvania 15243, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Vanderbilt Health One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Centro Médico Viamonte
    Caba, Buenos Aires C1120AAC, Argentina
  • Investigaciones Medicas Imoba Srl
    Caba, Buenos Aires C1179AAB, Argentina
  • Instituto Centenario
    Caba, Buenos Aires C1204AAD, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
  • Stat Research S.A.
    Ciudad Autónoma de Buenos Aire, Buenos Aires C1023AAB, Argentina
  • Glenny Corp
    Buenos Aires, Ciudad Autónoma De Buenos Aire 1430, Argentina
  • CEMEDIAB
    C.a.b.a., Ciudad Autónoma De Buenos Aire C1205AAO, Argentina
  • Instituto Médico Especializado (IME)
    Buenos Aires, 1405, Argentina
  • Sanatorio Norte
    Santiago del Estero, 4200, Argentina
  • CEDOES
    Vitória, Espírito Santo 29055450, Brazil
  • Cline Research Center
    Curitiba, Paraná 80030-480, Brazil
  • Quanta Diagnóstico e Terapia
    Curitiba, Paraná 80040-110, Brazil
  • CPCLIN
    Sao Paulo, São Paulo 01228-200, Brazil
  • BR Trials - Ensaios Clinicos e Consultoria
    Sao Paulo, São Paulo 03325-050, Brazil
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 22241-180, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Advanced Clinical Research, LLC
    Bayamon, 00961, Puerto Rico
  • Manati Center for Clinical Research
    Manati, 00674, Puerto Rico
  • Ponce Medical School Foundation Inc.
    Ponce, 00716, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2023, 24 months.

Results were first posted in May 2024, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 7, 2020
StartActual
Mar 29, 2021
Primary completionActual
Apr 20, 2023
CompletionActual
May 12, 2023
Results first posted
May 16, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04657016
Responsible party
Sponsor
First posted
Dec 7, 2020
Start date
Mar 29, 2021
Primary completion
Apr 20, 2023
Completion
May 12, 2023
Results posted
May 16, 2024
Last update
May 16, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion